Eyal Rubin
2023
In 2023, Eyal Rubin earned a total compensation of $1M as Senior Vice President and Chief Financial Officer at Protalix BioTherapeutics, a 3% decrease compared to previous year.
Compensation breakdown
| Bonus | $302,507 |
|---|---|
| Option Awards | $114,925 |
| Salary | $287,692 |
| Stock Awards | $227,331 |
| Other | $96,580 |
| Total | $1,029,035 |
Rubin received $302.5K in bonus, accounting for 29% of the total pay in 2023.
Rubin also received $114.9K in option awards, $287.7K in salary, $227.3K in stock awards and $96.6K in other compensation.
Rankings
In 2023, Eyal Rubin's compensation ranked 1,175th out of 2,983 executives tracked by ExecPay. In other words, Rubin earned more than 60.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,175 out of 2,983 | 61st |
Division Manufacturing | 700 out of 1,637 | 57th |
Major group Chemicals And Allied Products | 468 out of 906 | 48th |
Industry group Drugs | 457 out of 869 | 47th |
Industry Biological Products, Except Diagnostic Substances | 132 out of 211 | 37th |
Source: SEC filing on April 29, 2024.
Rubin's colleagues
We found two more compensation records of executives who worked with Eyal Rubin at Protalix BioTherapeutics in 2023.
News
Protalix BioTherapeutics CEO Dror Bashan's 2023 pay jumps 83% to $2.7M
April 29, 2024
Protalix BioTherapeutics CEO Dror Bashan's 2022 pay jumps 27% to $1.5M
May 18, 2023
Protalix BioTherapeutics CEO Dror Bashan's 2021 pay slips 14% to $1.2M
April 29, 2022
Protalix BioTherapeutics CEO Moshe Manor's 2019 pay slips 14% to $616K
April 15, 2020